Dordaviprone is an investigational new drug that is being evaluated for the treatment of diffuse intrinsic pontine glioma (a type of brain tumor).

[1] It is dopamine receptor D2 antagonist and an allosteric activator of the mitochondrial caseinolytic protease P.[2]

This pharmacology-related article is a stub.

You can help Wikipedia by expanding it.